van der Werf-Messing B, van Gilse H A
Br J Cancer. 1971 Sep;25(3):423-7. doi: 10.1038/bjc.1971.54.
A series of 33 patients with metastatic renal cancer and evidence of progression of the disease-apart from pulmonary metastases-was treated with hormones (progestogens in 31 cases, androgens in 2 cases) at the Rotterdamsch Radio-Therapeutisch Instituut. Complete or partial spontaneous regression (or non-progression of pulmonary metastases) before hormone treatment was observed in 8 patients (24%). A favourable subjective response to hormone treatment was obtained in 12 patients (36%), while a positive objective response was obtained in 2 (or 3) cases (6-9%).A favourable response was obtained slightly more frequently in men than in women. The hormonal effect was not demonstrably related to any of the following factors: age of the patient, type of progestogen used, the behaviour of concomitant pulmonary metastases, or the presence or absence of the primary growth.The prognosis was unaffected by hormone therapy, but the 2 year survival rate was significantly higher in patients that showed signs of spontaneous regression of pulmonary metastases, as compared with those without these signs.
鹿特丹放射治疗研究所对33例转移性肾癌患者进行了治疗,这些患者除肺转移外均有疾病进展的证据,采用激素治疗(31例用孕激素,2例用雄激素)。8例患者(24%)在激素治疗前出现完全或部分自发消退(或肺转移无进展)。12例患者(36%)对激素治疗有良好的主观反应,2(或3)例(6 - 9%)有阳性客观反应。男性获得良好反应的频率略高于女性。激素效应与以下因素均无明显关联:患者年龄、所用孕激素类型、伴随肺转移的情况或原发肿瘤的有无。激素治疗对预后无影响,但与无肺转移自发消退迹象的患者相比,有肺转移自发消退迹象的患者2年生存率显著更高。